MedPath

Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancer

Phase 2
Conditions
nresectable hepatic metastasis of colorectal cancer
Registration Number
JPRN-UMIN000004310
Lead Sponsor
Kyoto University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
35
Inclusion Criteria

Not provided

Exclusion Criteria

1. Brain metastasis, brain tumor 2. symptomatic cerebrovascular disease 3. active bleeding 4. uncontrolled hypertention etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The ratio of R0 resection or clinical CR
Secondary Outcome Measures
NameTimeMethod
Safety, The ratio of R0 hepatic resection, overall response rate, pathological response rate, progression free survival, 2-year survival rate, Compliance of initial regimen, relative dose intensity
© Copyright 2025. All Rights Reserved by MedPath